Ingalls & Snyder LLC Bluebird Bio, Inc. Transaction History

Ingalls & Snyder LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 27, 2021	SELL	$27.5 - $37.92 $219,835 - $303,132	-7,994 Closed	0 $0
Q3 2020 Oct 21, 2020	SELL	$34.44 - $43.75 $34,440 - $43,750	-1,000 Reduced 11.12%	7,994 $431,000
Q2 2020 Jul 31, 2020	BUY	$27.12 - $45.97 $542 - $919	20 Added 0.22%	8,994 $549,000
Q1 2020 Apr 22, 2020	SELL	$26.16 - $63.5 $21,189 - $51,435	-810 Reduced 8.28%	8,974 $412,000
Q4 2019 Jan 15, 2020	SELL	$46.96 - $61.67 $227,990 - $299,407	-4,855 Reduced 33.16%	9,784 $859,000
Q3 2019 Oct 16, 2019	SELL	$59.47 - $93.1 $11,180 - $17,502	-188 Reduced 1.27%	14,639 $1.34 Million
Q2 2019 Jul 11, 2019	BUY	$75.84 - $105.21 $1.12 Million - $1.56 Million	14,827 New	14,827 $1.89 Million

144

63.2M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $644M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

Stay updated on Ingalls & Snyder LLC with notifications on news.